Stock Exchange & Press Releases 2022

Print Print this release
June 01, 2022

Bittium Exhibits Home Sleep Apnea Testing Solutions at Sleep 2022 Congress in Charlotte, USA

Press release

Free for publication on June 1st, 2022, at 1.15 p.m. (CEST +1)

Bittium Exhibits Home Sleep Apnea Testing Solutions at Sleep 2022 Congress in Charlotte, USA

Oulu, Finland, June 1st, 2022 – Bittium’s advanced Home Sleep Apnea Testing Solution Bittium Respiro™[1] will be on display at Sleep 2022. The event is a major congress on sleep medicine and research to be held in Charlotte, North Carolina, on 4-8 June 2022.

According to research, there are more than 936 million people in the world with sleep apnea[2]. Sleep apnea is a serious medical condition and if left untreated, it is associated with an array of adverse health consequences, including cardiovascular disease, metabolic disorders, diabetes, cognitive impairment, and depression. Registration of sleep-related breathing disorders (polygraphy) is a quick, easy, and cost-effective way for a patient to determine if the patient has a sleep related breathing disorder and, if necessary, to get access to treatment quickly.

Bittium Respiro™ is an end-to-end solution consisting of a measuring device, analysis software, tailored accessories, and a service platform that utilizes artificial intelligence to speed up analysis work. The solution pre-analyses the massive amount of measurement data and converts it to a more visual and informative format. This makes it easier and quicker for healthcare personnel to perform further analysis and diagnosis.

All Bittium’s medical products can be integrated with the cloud-based back-end systems enabling seamless workflow and analysis of data regardless of location. These innovations not only equip clinicians with smarter diagnostics tools but also offer healthcare providers more efficient, time- and resource-saving solutions that are well suited for remote, preventative, and home-based care. The importance of remote care and remote monitoring has increased during the Covid-19 pandemic due to insufficient medical resources and cost pressures. Bittium’s remote monitoring and remote diagnostics solutions can provide solutions for these challenges and allow access to treatment for more patients.

Bittium’s Medical Technologies team will be at stand 665 at the event.

For more information about Bittium Respiro™, please visit or contact our sales at

To register for the event, please .

Further information:

Antti Näykki
Senior Vice President, Medical Technologies
Tel. +358 40 344 3507

Main media


In the field of healthcare technology, Bittium offers solutions for the measurement and monitoring of biosignals in the areas of cardiology, neurophysiology, and sports medicine. In addition, Bittium specializes in the development of reliable, secure communications and connectivity solutions, leveraging its 35-year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, and customized solutions based on its product platforms and R&D services. Net sales in 2021 were EUR 86.9 million and operating profit was EUR 3.2 million. Bittium is listed on Nasdaq Helsinki.

[1] Bittium Respiro™ is designed to be compliant with Medical Devices Regulation (MDR). Not yet available as a commercial product. Not available in the US.

[2] Benjafield et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respiratory Medicine 2019.